Trial
NCT03149159
Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Medical University of South Carolina
Collaborators
Bristol-Myers Squibb
Condition
Clear Cell Renal Cell Carcinoma
Intervention
Nivolumab
Why stopped
This study is withdrawn due to feasibility issues.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-06-18